Biotech entity
Of the tracked stories, 1 of 2 also mention Collegium, the most common co-covered peer. The clearest coverage concentration is gene-therapy: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 7 original sources each.
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Collegium, the most common co-covered peer. The clearest coverage concentration is gene-therapy: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 7 original sources each. Intellia Therapeutics appears in 2 tracked Biotech stories from February 26, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Intellia Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Functional Cure Declared
Medical reports confirm the patient is effectively cured of the rare disease.
Long-term Follow-up
B.C. patient reports zero attacks one year after single dose.
Phase 1/2 Results
Intellia releases early data showing significant reduction in HAE attacks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.
Intellia Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
